Evidence map›Paper›PMID 37123403›Full record

ArticleFrontiers in cell and developmental biology2023

Interrogating the CD27:CD70 axis in αCD40-dependent control of pancreatic adenocarcinoma.

Awndre Gamache, Claire Conarroe, Sara Adair, Todd Bauer, Frederic Padilla, Timothy N J Bullock

Open access · goldAbstract read
In one paragraph

Article in Frontiers in cell and developmental biology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
0.7field-weighted citation impact, top 24% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 3 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 3 institutions in 1 country.

Awndre GamacheDepartment of Pathology, School of Medicine, University of Virginia, Charlottesville, VA, United States.
Claire ConarroeDepartment of Pathology, School of Medicine, University of Virginia, Charlottesville, VA, United States.
Sara AdairDepartment of Surgery, University of Virginia, Charlottesville, VA, United States.
Todd BauerDepartment of Surgery, University of Virginia, Charlottesville, VA, United States.
Frederic PadillaFocused Ultrasound Foundation, Charlottesville, VA, United States.
Timothy N J BullockDepartment of Pathology, School of Medicine, University of Virginia, Charlottesville, VA, United States.
Carter Center · USUniversity of Virginia · USFocused Ultrasound Foundation · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Immune checkpoint blockade immunotherapy has radically changed patient outcomes in multiple cancer types. Pancreatic cancer is one of the notable exceptions, being protected from immunotherapy by a variety of mechanisms, including the presence of a dense stroma and immunosuppressive myeloid cells. Previous studies have demonstrated that CD40 stimulation can remodel the tumor microenvironment in a manner that promotes effector immune cell responses and can cooperate with immune checkpoint inhibition for durable tumor control mediated by T cells. Here we confirm the capability of this combination therapy to dramatically, and durably, control pancreatic cancer growth in an orthotopic model and that the immune memory to this cancer is primarily a function of CD4

Indexed as

CD27CD40CD70CPI therapyKPCPDACTIL activation

Identifiers

PMID37123403
PMCPMC10130518
OpenAlexW4365148426

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.